Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31719401 | 0.76 | P2RY12 (0.44) | CYP2C9CYP2C19P2RY12 | |
| SCHEMBL15351363 | 0.74 | CYP2C9 (0.49) | ALDH1A1L3MBTL1CYP2C9CYP2C19P2RY12 | |
| SCHEMBL28080919 | 0.74 | CYP2C9 (0.49) | ALDH1A1L3MBTL1CYP2C9CYP2C19P2RY12 | |
| SCHEMBL31719406 | 0.73 | DPP4 (0.50) | ALDH1A1L3MBTL1CYP2C9CYP2C19P2RY12 | |
| Hydrochloric Acid SCHEMBL15350755 | 0.73 | CYP2C9 (0.48) | ALDH1A1L3MBTL1CYP2C9CYP2C19P2RY12 | |
| SCHEMBL2686398 | 0.72 | CYP2C9 (0.46) | ALDH1A1KDM4ELMNAMAPTCYP2C9 | |
| SCHEMBL15449653 | 0.72 | CYP2C9 (0.56) | ALDH1A1KDM4EL3MBTL1MAPTCYP2C9 | |
| SCHEMBL27677948 | 0.70 | ALDH1A1 (0.47) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL23501671 | 0.70 | MEN1 (0.67) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL29933866 | 0.70 | MEN1 (0.67) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1775283-A1 | 3-AMINOBENAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | ALDH1A1 1417/4885KDM4E 3327/4885LMNA 4503/4885 |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | TRPV1, TRPV6, TRPV3 | ALDH1A1 1481/4885KDM4E 3049/4885LMNA 4457/4885 |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | ALDH1A1 1643/4885KDM4E 3809/4885LMNA 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.